MyoKardia (MYOK) Tops Q4 EPS by 20c

MyoKardia (NASDAQ: MYOK) reported Q4 EPS of ($0.21), $0.20 better than the analyst estimate of ($0.41). Collaboration & License revenue for the quarter came in at $5.6 million versus the consensus estimate of $6.08 million.

For earnings history and earnings-related data on MyoKardia (MYOK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c